Skip to main content
RTW Biotech Opportunities Ltd logo

RTW Biotech Opportunities Ltd — Investor Relations & Filings

Ticker · RTW ISIN · GG00BKTRRM22 LEI · 549300Q7EXQQH6KF7Z84 IL Financial and insurance activities
Open in API
Filings indexed 545 across all filing types
Latest filing 2025-07-15 Net Asset Value
Country GG Guernsey
Listing IL RTW

About RTW Biotech Opportunities Ltd

https://www.rtwfunds.com/rtw-biotech-op…

RTW Biotech Opportunities Ltd is an investment fund that focuses on identifying and investing in transformative assets with high growth potential across the global life sciences sector. The company's portfolio is primarily composed of biotechnology and medical technology companies. Managed by RTW Investments, LP, a specialized life sciences investment firm, the fund leverages deep scientific expertise to support companies throughout their entire lifecycle, from early-stage private ventures to publicly traded entities. The investment strategy aims to provide capital and strategic support to advance the development of innovative therapies and technologies.

Recent filings

Filing Released Lang Actions
Monthly Valuation Update and Factsheet
Net Asset Value Classification · 98% confidence The document is titled 'Monthly Valuation Update and Factsheet' and explicitly states the unaudited net asset value (NAV) as of 30 June 2025. It includes detailed portfolio holdings, performance metrics (NAV per share), and sector commentary. This content aligns perfectly with the definition of a regular update of Net Asset Value, primarily for investment funds. Although it contains factsheets, the core purpose is the NAV reporting. Therefore, the most specific classification is NAV.
2025-07-15 English
Merck to acquire Verona Pharma
M&A Activity Classification · 99% confidence The document is identified by the RNS Number (4492Q) and contains a headline announcing a significant corporate event: 'Merck to acquire Verona Pharma'. The text details the terms of the acquisition, the impact on the reporting company's portfolio (RTW Biotech Opportunities Ltd), and includes commentary from the CIO. This is a typical announcement made via the Regulatory News Service (RNS) of the London Stock Exchange regarding a material event concerning a portfolio holding, which often falls under general regulatory announcements or M&A activity. Since the document is an announcement about a transaction involving another company (Merck acquiring Verona Pharma, a portfolio company of RTW), and it is distributed via RNS, it fits best as a general Regulatory Filing (RNS) or potentially M&A Activity (TAR). Given the structure (RNS Number, LSE context, general announcement format) and the fact that it is an announcement about an external M&A event rather than a formal M&A proposal document for the reporting company itself, RNS is the most appropriate general classification for this type of market disclosure. The length (6852 chars) is substantial enough that it is not just a brief 'Report Publication Announcement' (RPA).
2025-07-10 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled as an 'RNS Number' filing and contains the header 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, specifically detailing the percentage of voting rights crossed or reached (in this case, crossing below 5.00% to 4.99%). This directly corresponds to the definition of a Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2025-07-03 English
Total Voting Rights
Regulatory Filings Classification · 95% confidence The document is a formal notification of 'Total Voting Rights' issued by RTW Biotech Opportunities Ltd in accordance with the FCA's Disclosure Guidance and Transparency Rules (DTR 5.6.1). It provides the total number of shares in issue and the resulting voting rights denominator for shareholders. This type of regulatory disclosure regarding share capital and voting rights does not fit into specific categories like 'Major Shareholding Notification' (which is for individual investors) or 'Share Issue' (which is for new capital changes), and it is a standard regulatory announcement distributed via RNS. Therefore, it is classified as a Regulatory Filing (RNS).
2025-07-01 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from RTW Biotech Opportunities Ltd regarding the repurchase of 100,000 of its own ordinary shares to be held in treasury. It explicitly mentions 'Transaction in Own Shares' in the title and provides details on the number of shares, price, and the impact on total voting rights. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-06-26 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from RTW Biotech Opportunities Ltd regarding the repurchase of 100,000 of its own ordinary shares to be held in treasury. It explicitly mentions 'Transaction in Own Shares' in the title and provides details on the number of shares, price, and the impact on total voting rights. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2025-06-25 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.